MarketScanners
Long

EXEL Climbing Ahead of FDA Decision

NASDAQ:EXEL   EXELIXIS INC
139 0 0
$EXEL shares starting to break-out.FDA decision scheduled to Nov. 29. "optimists like cabozantinib's chances for approval" says Motley Fool. Looks like negative over-all market conditions weighing in on the stock move. Watch this one!

http://www.fool.com/investing/general/2012/11/25/2-important-decisions-to-watch-for-this-week-in-th.aspx
English
English (UK)
English (IN)
Deutsch
Français
Español
Italiano
Polski
Türkçe
Русский
Português
Bahasa Indonesia
Bahasa Melayu
ภาษาไทย
Tiếng Việt
日本語
한국어
简体
台灣
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out